The Risk of Psychiatric Disorders in Finasteride Users with Benign Prostatic Hyperplasia and Androgenetic Alopecia: A Population-Based Case-Control Study

    August 2024 in “ Australasian Journal of Dermatology ”
    Anna Lyakhovitsky, Boaz Amichai, Eran Galili, Arnon D. Cohen, Khalaf Kridin, Zvi Segal, Doron Netzer
    Image of study
    TLDR Finasteride users have a very low risk of mental health issues, but those with hair loss may have slightly higher anxiety and depression.
    This large-scale population-based case-control study investigated the association between finasteride therapy for benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA) and the emergence of psychiatric disorders. The study included 307 men with BPH and 23,227 men with AGA, along with their respective control groups. Results showed that 2.3% of BPH patients experienced mental health outcomes, with no significant increase compared to controls. However, AGA patients had slightly higher rates of anxiety and depression compared to controls (0.6% vs. 0.4% and 0.5% vs. 0.4%, respectively). Multivariate regression models identified finasteride as a risk factor for anxiety (OR 1.449) and depression (OR 1.439) in AGA patients. Overall, finasteride users had a very low rate of adverse mental health effects, with no increase in psychological sequelae in BPH patients and a slight increase in anxiety and depression in AGA patients.
    Discuss this study in the Community →

    Research cited in this study

    18 / 18 results

    Related Community Posts Join

    6 / 1000+ results

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  42 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Why does finasteride stop working?

      in Finasteride/Dutasteride  26 upvotes 2 months ago
      Finasteride may seem less effective over time due to increased DHT sensitivity or aging, but it still suppresses DHT. Switching to dutasteride offers stronger DHT suppression but may increase estrogen levels.

      community 1 month of using fin, so happy

      in Progress Pictures  862 upvotes 4 months ago
      User had a hair transplant and used a finasteride and minoxidil spray for 6 months with no results. After adding finasteride tablets for 1 month, they saw significant hair growth improvement.

    Related Research

    6 / 6 results